Laddar populära aktier...
Oslo, Norway, 13 November 2024 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 120.
Oslo, Norway, 6 November 2024: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2024 financial results on Wednesday 13 No...
Oslo, Norway, November 5, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SS...
Press Release – Oslo, Norway, September 30, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris P...
Press Release – Oslo, Norway, September 27, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it entered into an ag...
Press Release – Oslo, Norway, September 17, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris P...
Oslo, Norway, 7 August 2024 - Photocure ASA (OSE:PHO), The Bladder Cancer Company, today reported Hexvix®/Cysview® revenues of NOK 122.
Oslo, Norway, 31 July 2024: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2024 financial results ...
Oslo, Norway, July 15, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has entered into a strategic agre...
Press Release – Oslo, Norway, June 4, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announces that it has commenced acti...
Oslo, Norway, 23 May 2024: Photocure ASA (OSE: PHO), held its annual general meeting on 23 May 2024 at 17:00 hours (CEST).
Oslo, Norway, 15 May 2024 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 116.
Press Release – Oslo, Norway, May 12, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmac...
Oslo, Norway, 8 May 2024: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2024 financial results on Wednesday 15 May 202...
Press Release – Oslo, Norway, May 7, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress...
Oslo, Norway, 30 April 2024: Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 23 May 2024 at 17...
Oslo, Norway, 30 April 2024: Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2023.
Press Release – Oslo, Norway, April 30, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the Ameri...
Oslo, Norway, 25 April 2024 – Photocure ASA (the "Company") (OSE: PHO) refers to its previous stock exchange announcement on 21 December 202...
Press Release – Oslo, Norway, April 8, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congre...
OSLO, Norway, April 5, 2024 – Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Executive Officer, Da...
Press release – Oslo, Norway, March 28, 2024: Photocure ASA, The Bladder Cancer Company, announces the publication of the study “Racial Diff...
Press Release – Oslo, Norway, March 18, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharm...
Press Release – Oslo, Norway, February 23, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Ph...
Press Release – Oslo, Norway, February 22, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Ph...
Oslo, Norway, 21 February 2024 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 114.
Oslo, Norway, 19 February 2024: Photocure ASA (Photocure, PHO: OSE) will announce the fourth quarter and preliminary full year 2023 financia...
Oslo, Norway, January 29, 2024: Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that its partner Asieris presented Phase III...
Oslo, Norway, 20 December 2023 - Photocure ASA (the "Company") (OSE: PHO) cancels up to 1,400,428 options and has subsequently re-issued 399...
Press release – Oslo, Norway, December 1, 2023: Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that new evidence from routi...
Press Release – Oslo, Norway, November 29, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Ph...
Press Release – Oslo, Norway, November 20, 2023: Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces its participation in four i...
Oslo, Norway, 8 November 2023 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 107.
Oslo, Norway, 1 November 2023: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2023 financial results on Wednesday 8 Nov...
Press Release – Oslo, Norway, October 12, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pha...
Press Release – Oslo, Norway, October 7, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Phar...
Press release – Oslo, Norway, October 6, 2023: Photocure ASA, The Bladder Cancer Company, announces the publication of “A cost-consequences ...
Oslo, Norway, 28 September 2023: Photocure, The Bladder Cancer Company, announces changes to the composition of its Board of Directors.
Press Release – Oslo, Norway, September 20, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris P...
Oslo, Norway, 30 August 2023: Board member Dylan Hallerberg has on 29 August 2023 acquired 150,000 shares at an average price of NOK 43.
Press Release – Oslo, Norway, August 11, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Phar...
Oslo, Norway, 9 August 2023 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 115.
Oslo, Norway, 3 August 2023: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2023 financial results...
Press Release – Oslo, Norway, July 6, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmac...
Oslo, Norway, 24 May 2023 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.
Oslo, Norway, 10 May 2023 - Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 105.
Oslo, Norway, 3 May 2023: Photocure ASA (OSE: PHO), held its annual general meeting on 3 May 2023 at 17:00 hours (CET).
Oslo, Norway, 3 May 2023: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2023 financial results on Wednesday 10 May 202...
Press Release – Oslo, Norway, May 2, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that results from the Nordic Regi...
Oslo, Norway, 12 April 2023: Photocure ASA today announces the publication of the Annual Report and integrated ESG report for 2022.
Oslo, Norway, 12 April 2023: Photocure ASA (OSE: PHO), calls for the annual general meeting of Photocure ASA to be held on 3 May 2023 at 17:...
Oslo, Norway, 30 March 2023 - Photocure ASA (the "Company") (OSE: PHO) has granted share options to employees.
Oslo, Norway, March 21, 2023 – Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces Karl Storz’s continued commitment to blue lig...
Oslo, Norway, March 14, 2023: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abs...
Oslo, Norway, 23 February 2023 Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 94.
Press release – Oslo, Norway, February 20, 2023: Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data from...
Oslo, Norway, 16 February 2023: Photocure ASA (Photocure, PHO: OSE) will announce the fourth quarter and preliminary full year 2022 financia...
Press release – Oslo, Norway, January 3, 2023: Photocure ASA, The Bladder Cancer Company, announces the publication of the study “Clinical a...
Press release – Oslo, Norway, December 5th, 2022: Photocure ASA, The Bladder Cancer Company, announces that new evidence was presented at th...
Oslo, Norway, November 7, 2022: Photocure ASA., (OSE: PHO), announces that The United States Centers for Medicare & Medicaid Services (CMS) ...
Press Release – Oslo, Norway, November 4, 2022: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pha...
Oslo, Norway, 2 November 2022: Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 96.
Oslo, Norway, 25 October 2022: Photocure ASA (Photocure, PHO: OSE) will announce the third quarter 2022 financial results on Wednesday 2 Nov...
Press release – Oslo, Norway, October 4, 2022: Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data and it...
Karl Storz and Photocure to collaborate on commercializing the high-definition system Press Release – Oslo, Norway, September 28, 2022: Pho...
Press release – Oslo, Norway, September 20th, 2022: Photocure ASA, The Bladder Cancer Company, announces the publication of first results fr...
Press release – Oslo, Norway, September 15, 2022: Photocure ASA (PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris P...
Press release – Oslo, Norway, September 8th, 2022: Photocure ASA, The Bladder Cancer Company, is delighted to continue supporting the global...
Press Release – Oslo, Norway, September 1, 2022: Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Dr...
Oslo, Norway, 10 August 2022: Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 99.
On August 9, 2022, Asieris Pharmaceuticals, a global biopharmaceutical company specializing in the discovery and development of innovative d...
Oslo, Norway, 4 August 2022: Photocure ASA (Photocure, PHO: OSE) will announce the second quarter and first half year 2022 financial results...
Oslo, Norway, July 27, 2022: Photocure ASA, The Bladder Cancer Company, announces that it has been informed by Karl Storz that the U.
High-definition blue light cystoscopic imaging showcased at the European Association of Urology (EAU) Congress, Amsterdam Press release - O...
Oslo, Norway, 13 June 2022: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 3 J...
Lower rates of bladder cancer recurrence and progression demonstrated in clinics with a high level of blue light cystoscopy (BLC[®]) use in ...
Oslo, Norway, 3 June 2022: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 1 Ju...
Oslo, Norway, 1 June 2022: Participants in Photocure ASA's ("Photocure" or the "Company") share option program have on 1 June 2022 exercised...
Oslo, Norway, 1 June 2022: Photocure ASA ("Photocure" or the "Company") has decided to initiate a buyback of up to 36,000 of its own shares ...
Press Release – Oslo, Norway, May 18, 2022: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the conclusion of a productive A...
Oslo, Norway, 11 May 2022: Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 81.
Oslo, Norway, 5 May 2022: Photocure ASA (Photocure, PHO: OSE) will announce the first quarter 2022 financial results on Wednesday 11 May 202...
Oslo, Norway, 28 April 2022: Photocure ASA (OSE: PHO), held its annual general meeting on 28 April 2022 at 17:00 hours (CET).
Oslo, Norway, 26 April 2022: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") (OSE: PHO) publ...
Oslo, Norway, 7 April 2022: Photocure ASA (OSE: PHO), calls for the annual general meeting of PHO to be held at Advokatfirmaet Selmer AS' pr...
Oslo, Norway, 6 April 2022: Photocure ASA today announces the publication of the Annual Report 2021, included the ESG report for 2021.
Press Release – Oslo, Norway, 29 March 2022, Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Execut...
Oslo, Norway, 16 March 2022: Reference is made to the stock exchange release by Photocure ASA ("Photocure" or the "Company") published on 14...
Oslo, Norway, 14 March 2022: Participants in Photocure ASA's ("Photocure" or the "Company") share option program have on 14 March 2022 exerc...
Press release – Oslo, Norway, March 11, 2022: Photocure ASA (PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris Pharm...
Press release – Oslo, Norway, 4 March 2022: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that it has entered into an excl...
Press release – Oslo, Norway, 28 February 2022: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of new resul...
Oslo, Norway, 23 February 2022: Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 94.
Oslo, Norway, 16 February 2022: Photocure ASA (Photocure, PHO: OSE) will announce the fourth quarter and preliminary full year 2021 financia...
Oslo, Norway, February 11, 2022: Photocure ASA (PHO: OSE), The Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (S...
Press Release – Oslo, Norway, 8 February 2022, Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Exec...
Oslo, Norway, February 7, 2022: Photocure ASA, The Bladder Cancer Company, announces U.
Press Release – Oslo, Norway January 6, 2022, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solut...
